Data from Phase II trials are analyzed using various _biostatistical_ methods. The analysis focuses on: - Efficacy endpoints: Measuring the treatment's effect on the condition. - Safety endpoints: Tracking adverse events and side effects. - Subgroup analysis: Examining how different subgroups respond to the treatment.
